
Technology transfer represents a critical bridge between development and commercial manufacturing. This complex process — moving product and process knowledge between development and manufacturing teams or between different manufacturing sites — demands precision at every stage.
The implications of technology transfer extend beyond knowledge sharing. Each decision during this process directly impacts manufacturing efficiency, regulatory compliance, and ultimately, time to market. A well-executed tech transfer can accelerate commercialization timelines, avoiding oversights or missteps that could cascade into significant delays and additional costs.
The Technology Transfer Landscape
The pharmaceutical manufacturing environment continues to evolve, driven by increasing demand for sterile products and an ever-more complex regulatory landscape.1 Recent updates to regulations, including Annex 1, have heightened requirements for manufacturing processes and controls, particularly in sterile manufacturing environments.
Success in this landscape requires careful navigation of multiple phases. The tech transfer journey progresses through new product introduction, engineering and first clinical runs, process performance qualification (PPQ), and finally, commercial manufacturing preparation. Each phase builds upon previous steps, making thorough execution essential for both regulatory approval and commercial viability.
Market pressures add another layer of complexity to this process. As pharmaceutical companies face increasing competition, the drive to reduce time to market intensifies. This acceleration must be balanced against the need for scalable, efficient processes.
By examining common challenges and implementing strategic solutions, companies can build a more efficient path from development to commercial manufacturing. This helps establish a strong foundation for long-term manufacturing success.
Challenge 1: Bridging the R&D-Commercial Manufacturing Gap
Research and development teams often focus on product formulation and early-stage development without fully considering commercial manufacturing requirements. This disconnect manifests in practical challenges that can significantly impact the tech transfer process, frequently necessitating costly reformulations and extending development timelines.
The solution to this challenge is adopting a commercial manufacturing mindset from the earliest stages of development. This approach requires meaningful collaboration between R&D and commercial stakeholders from project initiation. By including manufacturing expertise in early development decisions, teams can better anticipate scaling challenges and design processes that translate effectively to commercial production.
Success also depends on careful material selection and supplier qualification. Organizations must work with suppliers capable of supporting both development and commercial-scale manufacturing, ensuring consistent material quality and availability throughout the product life cycle. This foresight helps prevent supply chain disruptions that could otherwise derail the tech transfer process.
Challenge 2: Managing Documentation
The importance of comprehensive documentation during tech transfer cannot be overstated, yet misalignment in knowledge and documentation transfer remains a persistent challenge. Commonly overlooked documents include cleaning recovery protocols, raw material qualifications, risk assessments, engineering run protocols, and process validation master plans.
A successful documentation strategy requires alignment with industry standards, particularly PDA Technical Report 65.2 By implementing thorough documentation practices from the start, organizations create a clear trail of decision-making and process development that supports both regulatory compliance and operational efficiency.
Challenge 3: Analytical Capabilities
Limited analytical capabilities can create unexpected bottlenecks. When organizations rely heavily on outsourced testing, real-time problem-solving becomes challenging, and timeline extensions often follow. The impact becomes particularly acute during critical phases such as method transfer and validation.
Developing robust in-house analytical capabilities offers a distinct advantage. Organizations with integrated analytical expertise can perform method development, qualification, and compendial verifications efficiently. This capability enables rapid troubleshooting and adjustment during tech transfer, supporting more predictable timelines.
Challenge 4: Navigating Regulatory Requirements
Regulatory requirements present another significant challenge, particularly for complex products and combination devices. Organizations often underestimate the scope of regulatory documentation needed, especially when dealing with products requiring additional submissions such as device master files.
Success requires careful planning and preparation. Manufacturing facilities must maintain current Establishment Inspection Reports (EIRs) and plan for extended stability programs, particularly for biologics which may require up to one year of stability data.3 Additionally, thorough homogeneity testing across batches helps ensure consistent product quality and supports regulatory submissions.
Challenge 5: Adapting to Emerging Trends
The pharmaceutical landscape continues to evolve, presenting new opportunities and challenges for tech transfer. The rise of biosimilars as patents expire, the increasing prevalence of 505(b)(2) submissions,4 and growing demand for innovative autoinjector technologies5 all require flexible and adaptive tech transfer approaches.
Organizations must ensure their capabilities align with current and emerging product and platform requirements. This alignment demands built-in flexibility within tech transfer processes, allowing teams to adapt to new trends while maintaining efficiency and compliance.
Achieving a Smooth Tech Transfer
Successful technology transfer requires a holistic approach that addresses each of these critical challenges. The key lies in preparation and foresight. Organizations that invest in addressing challenges proactively rather than reactively position themselves for success in an increasingly complex environment. This investment not only supports more efficient tech transfer processes but also builds a foundation for sustainable commercial manufacturing success.
Want to explore tech transfer in more detail? Download our white paper.
References
- Panchal, K., Katke, S., Dash, S.K., et al. An expanding horizon of complex injectable products: development and regulatory considerations. Drug Deliv Transl Res. 2023 Feb;13(2):433-472. doi:10.1007/s13346-022-01223-5
- Parenteral Drug Association. PDA Technical Report No.65 Revised 2022 (TR 65) Technology Transfer. 2022 Jun. https://www.pda.org/bookstore/product-detail/6680-tr-65-revised-technology-transfer
- Sangeetha, V.P., Remya, N.S., and Mohanan, P.V. Regulatory issues in biological products. Biomedical Product and Materials Evaluation. Woodhead Publishing. 2022:309-327. doi:10.1016/B978-0-12-823966-7.00005-0
- FDA. Determining Whether to Submit an ANDA or a 505(b)(2) Application. 2019 May. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-whether-submit-anda-or-505b2-application
- Ingle, R.G., and Fang, W.J. Prefilled dual chamber devices (DCDs) – Promising high-quality and convenient drug delivery system. International Journal of Pharmaceutics. 2021 Mar;597:120314. doi:10.1016/j.ipharm.2021.120314
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
The three key trends that will most impact drug development in 2025
The speed of change in the drug development and manufacturing sector requires its stakeholders to be proactive in understanding and addressing key trends and directions the industry is taking. As a global market of considerable size and significance, the value of which is anticipated to grow from $589.06 billion in 2024 to $632.71 billion in […]
Learn MoreMicroneedle array patch characterization recording
Microneedle array patches (MAPs) have the potential to transform delivery of medications and vaccines. While this innovative drug delivery format could result in improved efficiency across a wide range of therapeutics, it also brings critical challenges. To successfully move from concept to commercialization, MAP manufacturers must consider scalability, regulatory compliance, and other complexities. In this […]
Learn MoreMicroneedle array patch characterization presentation
Microneedle array patches (MAPs) are a transformative innovation in drug delivery, with the potential to redefine how medications and vaccines reach patients. MAPs promise a simpler, more effective way to deliver a wide range of therapeutics, but their journey from concept to commercialization is filled with critical challenges. From scaling manufacturing to ensuring regulatory compliance, […]
Learn MoreTech transfer commercial manufacturing mindset
Technology transfer (tech transfer) moves product and process knowledge between teams or partners and acts as a crucial bridge between ideation and commercialization. Especially for complex products like sterile injectables, a smooth tech transfer process is essential. In this white paper, discover valuable strategies to embrace a commercial manufacturing mindset from day one. Download your […]
Learn MoreHFA152a green propellant capabilities
With evolving regulations and a growing push for sustainability, switching pressurized metered-dose inhalers (pMDIs) to green propellants is becoming increasingly essential. One of the most promising low global warming potential (GWP) options is HFA152a. In this white paper, we share insights on transitioning to HFA152a. Download your copy to discover: An overview of sustainability regulations […]
Learn MoreSterile product introduction and tech transfers in a crowded market
The tech transfer landscape for sterile products is increasingly complex, with pressure to reduce time to market. Find out how to navigate common challenges and avoid costly delays or oversights in this presentation from our Director, Client Portfolio & Relationship Management, Kim Brown. Download your copy to explore: Benefits of a commercial manufacturing mindset How […]
Learn MoreEliminating the syringe with inhaled and microneedle vaccine delivery systems
Interest in inhaled and intradermal vaccine delivery systems isn’t just a modern innovation — one of history’s most effective vaccination campaigns also used mucosal or dermal delivery. In 1777, George Washington mandated smallpox inoculation for his troops using either arm scratches (intradermal) or nasal inhalation (mucosal), a strategy that proved crucial in the American victory.1 […]
Learn MoreLeading the way in low-GWP propellants
As regulations surrounding inhalation device sustainability evolve, we help you streamline the process of transitioning to low global warming potential (GWP) propellants. Clinical supply for green propellants HFA152a and HFO1234ze is already available, with commercial scale available this year and plans for further expansion. Download this information sheet to dive deeper into our low-GWP propellant […]
Learn MoreOpportunities and challenges for inhalation drug delivery of biologics
The biopharmaceutical industry is experiencing a transformative shift toward the development of biologic drugs, particularly in the realm of inhaled drug delivery. A significant portion of biologics, approximately 10%, are being developed for respiratory delivery.1 This burgeoning pipeline includes a diverse array of molecules and targets. However, this approach also presents unique formulation and device […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.